Jul. 2 at 2:57 PM
$CELZ The more realistic positive case is that CELZ waits for expanded-cohort follow-up before launching P3, which could push the start closer to mid-late 2027. The slower case is that FDA wants stronger 12-mo data, cleaner opioid-use data, or additional manufacturing work before green-lighting P3 which would likley push it into 2028. So even if the 180-day data is accepted, “moving quickly” probably means P3 preparation in late 2026 and a possible trial start in 2027.
A partnership is always possible, but the odds likely improve once CELZ some form of FDA P3 alignment. That probably points to the early to mid-2027 window. A buyout is possible too, but it is much more speculative before stronger durability data and a clearer regulatory path.
Spikes are always possible with CELZ, but a sustained breakout above the
$1.60 probably requires fresh clinical news, FDA alignment, strategic partnership interest, or non-dilutive funding.
